Skip to main content
  •   Home
  •   Download
  •   Manual
  •   Contact

Drug Combination Details

General Information of the Combination (ID: C39033)
Name Arsenic trioxide   NP Info  + 10058F4   Drug Info 
Structure +
Disease
Brain cancer [ICD-11: 2A00]
Investigative [1]
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. Enhancing Drug Efficacy by This Combination
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Experiment 1 Reporting the Effect of This Combination [1]
                    In-vitro Model Cells derived from glioblastoma multiforme patients Glioblastoma multiforme Homo sapiens
                    In-vivo Model For in vivo experiments, CSCs (5 * 104 cells) were implanted intracranially into 10 week-old female C.B17-lcr SCID mice.
                    Experimental
                    Result(s)
Arsenic trioxide drastically enhanced the anti-proliferative effect of 10058F4 but not apoptotic effects.
References
Reference 1 Arsenic trioxide sensitizes glioblastoma to a myc inhibitor. PLoS One. 2015 Jun 3;10(6):e0128288.
 Download Picture         KEGG Link      
Cite NPCDR
Visitor Map
Correspondence

X. N. Sun, Y. T. Zhang, Y. Zhou, X. C. Lian, L. L. Yan, T. Pan, T. Jin, H. Xie, Z. M. Liang, W. Q. Qiu, J. X. Wang, Z. R. Li, F. Zhu*, X. B. Sui*. NPCDR: natural product-based drug combination and its disease-specific molecular regulation. Nucleic Acids Research. 50(D1): 1324-1333 (2020). PMID: 34664659

Prof. Feng ZHU  (zhufeng@zju.edu.cn)

College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China


Prof. Xinbing SUI  (hzzju@hznu.edu.cn)

School of Pharmacy and Department of Medical Oncology, the Affiliated Hospital of Hangzhou Normal University, Hangzhou Normal University, Hangzhou, China